Emerald Health Therapeutics, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Full Time Employees
- 110
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 800 West Pender Street Vancouver BC Canada V6C 2X8
- IPO Date
- Jan 2, 2015
- CIK
- 0001768225
- Website
- emeraldhealth.ca
- Similar Companies
- Business
- Emerald Health Therapeutics, Inc. is a Canadian cannabis company engaged in the production, development, and commercialization of recreational, medical, and wellness-oriented cannabis products. The company offers a diversified product portfolio including dried flower, cannabis oils, capsules, vape cartridges, and cannabis-infused beverages, operating under its distinct consumer brands across recreational and medical cannabis markets. Founded in 2014 and headquartered in Vancouver, British Columbia, Emerald Health Therapeutics has expanded its operations with a Health Canada licensed processing facility in Victoria, BC, to support its manufacturing and distribution capabilities. Recently, the company completed strategic changes including the divestiture of its recreational and medical cannabis business assets to focus on its biopharmaceutical segment following the acquisition by Skye Bioscience in late 2022. Post-acquisition, Emerald shifted its focus to advancing clinical trials for novel cannabinoid-based drug candidates targeting ocular diseases and other therapeutic areas, emphasizing the development of pharmaceutical-grade cannabinoid formulations such as SBI-100 ophthalmic emulsion and SBI-200 synthetic cannabidiol derivatives. Emerald also continues to innovate within the cannabis consumer product space, highlighted by products like the Cranberry Citrus Live Rosin Beverage, which remains a top performer as of 2025. The company targets Canadian and international markets with its expanded portfolio, combining both consumer-facing cannabis products and a growing pharmaceutical pipeline stemming from its research collaboration and development efforts. This strategic pivot reflects Emerald's dual commitment to delivering consumer cannabis innovations alongside advancing cannabinoid-based therapeutics through clinical and regulatory pathways.
Skye Bioscience concludes merger with Emerald Health Therapeutics and unveils goals for 2022 and 2023
Skye Bioscience says Emerald Health Therapeutics shareholders approve integration plan of arrangement; gets regulatory approval to begin first-in-human clinical study
Skye Bioscience signs agreement to merge with Emerald Health Therapeutics
Emerald Health Therapeutics Leaving 'Saturated' Cannabis Market, Will Focus On Pharmaceuticals
Emerald Health Therapeutics Announces Chief Financial Officer Transition
Emerald Health Therapeutics, Inc. (EMHTF) CEO Riaz Bandali on Q2 2021 Results - Earnings Call Transcript
Emerald Health Therapeutics Reports 2021 Second Quarter Financial Results and Provides Corporate Update
Emerald Health Therapeutics to Host 2021 Second Quarter Financial Results Conference Call on Tuesday, August 31, 2021 at 10:30 AM ET
Emerald Health Therapeutics Hires VP Sales & Marketing
Emerald Health Therapeutics Executive Chairman Avtar Dhillon Resigns
Emerald Health Therapeutics Retains Listing Agent to Sell Previously-Closed Greater Vancouver Cannabis Cultivation Facility
Emerald Health Therapeutics Licenses New Proprietary Cannabis Dried Flower Format Patent for use in United States
Emerald Health Therapeutics Appoints Moe Jiwan as Chief Operating Officer
Emerald Health Therapeutics, Inc. (EMHTF) CEO Riaz Bandali on Q4 2020 Results - Earnings Call Transcript
Emerald Health Therapeutics Reports 2020 Year-end and Fourth Quarter Financial Results and Provides Corporate Update
Emerald Health Therapeutics Confirms Effective Listing Date on Canadian Securities Exchange
Emerald Health Therapeutics Establishes Partnership with Spanish Greenhouse Grower for GMP-Certified Cannabis
Emerald Health Therapeutics to Close Greater Vancouver Production Facility
Emerald Health Therapeutics Receives $20.5M Payment from Village Farms and Outlines Growth Plans
Emerald Health Therapeutics Promotes Two Executives to Senior Roles